Physician profile
Michael Kaplowitz
NPI 1255308078
$5,053.15
in general payments reported to CMS, 2019-2025
17 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,527 · 2020: $442 · 2021: $517 · 2022: $653 · 2023: $651 · 2024: $206 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,914.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $1,646.54 | 2019-2023 | Equetro |
| Neurocrine Biosciences, INC. | $612.06 | 2019-2025 | |
| Alkermes, INC. | $608.37 | 2021-2025 | Lybalvi, Aristada |
| Almatica Pharma LLC | $321.94 | 2021-2025 | Loreev Xr |
| Teva Pharmaceuticals USA, INC. | $321.33 | 2019-2025 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $307.96 | 2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $259.67 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $231.67 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $154.69 | 2023-2025 | Auvelity |
| Shire North American Group INC | $139.28 | 2019 | |
| Genzyme Corporation | $128.23 | 2025 | |
| Abbvie INC. | $112.50 | 2025 | |
| Avanir Pharmaceuticals, INC. | $62.06 | 2022 | |
| Janssen Pharmaceuticals, INC | $50.50 | 2019 | |
| Lundbeck LLC | $48.09 | 2022-2023 | Rexulti |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $29.75 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $18.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kaplowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.